COLL · Collegium Pharmaceutical, Inc
$21.87
-0.15 (-0.68%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$721.76M
Shares
32.56M
Volume · Oct 5
975.39K
Avg daily vol (3M)
735.38K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$22.02
Open$21.97
Day$21.64–22.38
52W close$21.82–49.84
Avg vol 30d890K
Short int5.7M · 17.4% float · 6.0d
Short vol56%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$808.21M
Trailing 12 months
Net income (TTM)
$47.91M
Trailing 12 months
Revenue growth YoY
+6.3%
Year over year
Operating margin
19.5%
Trailing 12 months
P / E (TTM)
17.8
Trailing earnings · reciprocal yield 5.6%
FCF yield
45.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-16.9%
Year over year · fewer shares
Price change (1Y)
-35.8%
Trailing year
Short interest
17.4%
Latest settlement · 6.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−38%
below
Price vs 50-day avg
−18%
below
RSI (14)
31
neutral
MACD trend
Positive
52-week position
1%
near low
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−38%
trailing
YTD return
−52%
this year
Relative strength
−50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $36 — 200d above 50d
Institutional flow
Distributing
1 of 280 funds reported for Sep 30 · net -213 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
17.43% of float · ▼ -6.4% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
280 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+24%
Y/Y
Gross margin
59%
contracting
EPS growth
−7%
Y/Y
Free cash flow
$327.6M
Buyback
$150.0M
remaining
Balance sheet
$88.9M
net cash
Quant / Vol
risk profile
Volatility
44%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Adjusted EBITDA
· full-year 2026
Non-GAAP
Initiated
$445M – $470M
Guided vs delivered
· last 1 settled
Total revenue
2021
guided $330M – $340M
$276.87M
Miss −17.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−38%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
31
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $27 › 200d $36 — 200d above 50d
Institutional flow
Distributing
1 of 280 funds reported for Sep 30 · net -213 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
17.43% of float · ▼ -6.4% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
280 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $22
Now $22 · 1%
Range high $50
vs 200-day avg -38%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share non-GAAP | $3.67 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | 217.73M | Six Months Ended June 30, 2026 | — |
| Adjusted Operating Expenses non-GAAP | 135.93M | Six Months Ended June 30, 2026 | — |
| Adjusted weighted-average shares — diluted non-GAAP | 39,935,892 | the three months ended June 30, 2026 filing | — |
| AZSTARYS prescriptions growth | 1.9% | the quarter ended June 30, 2026 | — |
| Cash from operations | $71.3M | the quarter ended June 30, 2026 | — |
| JORNAY PM prescribers | 30,000 | the quarter ended June 30, 2026 | — |
| JORNAY PM prescriptions growth | 13.1% | the quarter ended June 30, 2026 | — |
| Market share in branded long-acting methylphenidate market | 29% | Q2'26 | — |
| Non-GAAP adjusted net income non-GAAP | 144.62M | Six Months Ended June 30, 2026 | — |
| Quarterly prescriber base (JORNAY PM) | 30K | Q2'26 | — |
| Quarterly prescriptions (JORNAY PM) | 210K | Q2'26 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COLL
this stock
Collegium Pharmaceutical, Inc
|
$721.76M | -52.4% | +23.6% | — | 17.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COLL | -2.3% | -7.1% | -38.2% | +0.9% | -52.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -2.0% | -6.6% | -50.4% | +0.0% | -65.3% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$150.00M
Spent (derived)
$0
Remaining
$150.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.